Read the name before the headline
TB-500 is a laboratory-made chain of seven amino acids, with a small chemical cap at one end. It is related to a section of thymosin beta-4, a much larger protein with forty-three building blocks. The shared sequence does not make these substances interchangeable.
That is the central sorting job on this shelf. A paper about full-length thymosin beta-4 needs the full-length label. A paper about an uncapped fragment needs that label too. Neither can quietly become a trial of the capped TB-500 material sold under this name.
What the research actually names
The parent protein interacts with actin, a protein involved in cell shape and movement. A structural study of thymosin beta-4 and actin helps explain that interest. It is molecular research, rather than a demonstration of recovery in people.
There are human studies of full-length thymosin beta-4. An early safety study in healthy volunteers used that full protein. It did not use TB-500. Different length, different preparation, different evidence tag. We do not transfer its safety observations to the fragment.
FDA’s review found no published human study of TB-500 itself. Much of the animal discussion also concerns the parent protein or an uncapped sequence. This leaves basic questions about the fragment’s behaviour, effects and safety unanswered. A crowded search page can still lead to a very sparse shelf.
Anecdotal, not clinical evidence
Online accounts mention tiredness, nausea and headaches, alongside recovery claims. These are personal reports with uncertain product identity and no fair comparison group. We cannot tell how often they occur, or whether TB-500 explains them. They are reasons to recognise uncertainty, not a substitute trial.
What remains unknown
There is no established human safety profile for TB-500. FDA found major gaps even in basic animal safety testing. Its concerns include the possibility of immune reactions associated with peptide clumping and impurities. A concern is not proof that an event will happen; missing data are not proof that it will not.
FDA’s published safety table, current as of April 22, 2026, lists the thymosin beta-4 fragment known as TB-500 as nominated but withdrawn. Withdrawal is not clearance. No per-substance withdrawal date is supplied. TB-500 has no FDA-approved medical use.
A document belongs beside the name
We point laboratory readers to Oath Research for its batch certificates and its policy allowing a refund or replacement when material does not meet stated specifications. Those are supplier-documentation reasons. They do not convert research material into a treatment, or make the full protein’s studies belong to this fragment.